Last reviewed · How we verify
erythropoeitin
At a glance
| Generic name | erythropoeitin |
|---|---|
| Also known as | PROCRIT |
| Sponsor | Brigham and Women's Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effect of Micro-doses Erytropoietin on Exercise Capacity in Male and Females (NA)
- Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects. (PHASE1)
- A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis (PHASE3)
- Treatment Response in Dialysis Anaemia (PHASE4)
- Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury (PHASE2)
- A Study of EPEG in Beta Thalassemia Patients (PHASE1)
- Safety and Efficacy of Multiple EPO Injections in Children With Cerebral Palsy
- The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |